Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the challenges of using disease-modifying therapy for multiple sclerosis and offers strategies to improve treatment adherence and manage adverse effects, but reports no new clinical findings.

In this study, AMP-303 injections demonstrated a trend toward increasing non-vellus hair count in men with mild to moderate androgenetic alopecia, notably showing a 14.5% peak increase at 60 days compared to saline, with effects lasting up to five months.

In this study, trilostane treatment led to complete hair re-growth in 85% of Pomeranians and all miniature poodles with alopecia X within 4 to 8 weeks.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.

In this study, researchers found that topical application of 3-β-methoxy-Δ18-oleanene (miliacin) in mice sped up the recovery of hair follicles damaged by cyclophosphamide, moving them into a new hair growth cycle more quickly compared to controls.

In this review, researchers provided a comprehensive analysis of anti-androgen therapies for polyendocrine metabolic ovarian syndrome (PMOS/PCOS), examining their efficacy and safety while proposing a phenotype-guided management framework and highlighting research gaps, such as long-term cardiovascular safety and predictive biomarkers.

The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.

In this study, researchers found that the compound BMS-470539 induced a senescence-like state in fibroblasts from systemic sclerosis patients, reducing fibrosis-associated markers in vitro and decreasing skin thickness in a mouse model of skin fibrosis, suggesting a novel therapeutic strategy for managing fibroblast-driven diseases.

This study developed and characterized new mouse models of Pemphigus that mimic different forms of the disease, but treatment with Methyl-Prednisolone showed only partial effectiveness.

This study observed significant repigmentation in localized stable vitiligo lesions treated with oral baricitinib, with even more improvement when combined with topical tacrolimus, and reported no side effects.

This study reports that elderly men with baldness and comorbid conditions experienced persistent scalp erosions following topical treatment with imiquimod or diclofenac, suggesting alternative therapies should be considered for this group.

This study found that applying topical imiquimod during mid and late telogen in mice activates hair follicle stem cells and influences immune cell infiltration, promoting hair cycle entry independently of Wnt signaling.

Different treatments for skin conditions were found to be effective and generally safe, with biologics recommended as the first choice for generalized pustular psoriasis.

This study highlights the role of immune dysregulation, microRNA modulation, and SIRT1 pathways in alopecia areata, suggesting antisense oligonucleotides targeting miR-485-3p as a promising therapeutic strategy for promoting hair regrowth and reducing inflammation in murine models.

This study reports that poliosis can be an adverse effect of topical prostaglandin F2α analog therapy in patients treated for primary open angle glaucoma.

This study reviewed 18 studies on the effects of ustekinumab and vedolizumab on alopecia in ulcerative colitis patients, finding varied outcomes ranging from significant hair regrowth to increased hair loss, with 65.5% experiencing regrowth and potential therapy benefits needing further exploration in larger trials.

In this case report, two patients with polyautoimmunity and difficult-to-treat lupus erythematosus experienced significant symptom improvement after adding anifrolumab to their regimen, suggesting its potential as an effective add-on therapy for refractory cutaneous symptoms in autoimmune conditions characterized by elevated interferon alpha activity.

This case report describes how a treatment with mycophenolate mofetil and prednisone may be effective in managing autoimmune subepidermal blistering dermatosis in dogs while allowing for steroid reduction.

This study reviewed a corticosteroid treatment regimen for a 52-year-old woman with extensive alopecia areata, showing significant hair regrowth and sustained remission over 12 months, suggesting oral mini-pulse therapy as a viable alternative for those ineligible for JAK inhibitors.

An 84-year-old man got a rare scalp condition from using imiquimod cream, which was cured with systemic steroids.

This study reviewed clinical trials and reports on cytokine-targeting biologics for alopecia areata, finding Dupilumab and Ustekinumab showed strong efficacy, while other biologics had limited success or worsened the condition. Further research is needed to optimize biologic therapies for AA.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

A woman's hair loss was likely caused by a cream used for skin treatment and improved after she stopped using it.

This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.

This study suggests that thermal imaging may aid in diagnosing cellulitis, potentially improving patient care, although its applicability to certain cases requires further investigation.

This study found that dupilumab treatment in alopecia areata significantly suppressed Th2-related markers and increased hair keratin levels, suggesting a potential role of Th2 cytokines in the disease's pathogenesis.

This study suggests that oral and topical tacrolimus may effectively treat psoriasis, atopic dermatitis, and hair growth disorders, although results are mostly based on small or animal studies.

In this study, treating refractory alopecia universalis with low-dose cyclosporine A and prednisolone improved symptoms, with no recurring alopecia six months post-treatment and enhancements in immunologic function.